Aprotinin in cardiac surgery - re-evaluation of the risks?

Abstract

The article describes the history of introducing aprotinin into cardio-surgical clinical practice and deals with the circumstances based on the results of BART study leading to its withdrawal from the global pharmaceutical market and with its recent re-authorization in some countries.

Keywords

• cardiac surgery
• fibrinolysis
• fibrinolytic inhibitors
• aprotinin